跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MOXICLAV DRY POWDER FOR ORAL SUSPENSION 156.25 mg/5 ml - HSA Drug Approval Details
Approvals
/
HSA
/
MOXICLAV DRY POWDER FOR ORAL SUSPENSION 156.25 mg/5 ml
Approved
THERAPEUTIC
MOXICLAV DRY POWDER FOR ORAL SUSPENSION 156.25 mg/5 ml
Medochemie Ltd – Factory B (CYPRUS)
🇸🇬 Health Sciences Authority
Approval Date
Jan 20, 1999
Approval ID
0224932aeecc5dd1
Company
Medochemie Ltd – Factory B (CYPRUS)
Type
Therapeutic
Approval Details
Approval Id
0224932aeecc5dd1
Drug Name
MOXICLAV DRY POWDER FOR ORAL SUSPENSION 156.25 mg/5 ml
Product Name
MOXICLAV DRY POWDER FOR ORAL SUSPENSION 156.25 mg/5 ml
Approval Number
SIN10690P
Approval Date
1999-01-20
Registrant
MEDOCHEMIE SINGAPORE PTE. LTD.
Licence Holder
MEDOCHEMIE SINGAPORE PTE. LTD.
Drug Type
Therapeutic
Forensic Classification
Prescription Only
Dosage Form
POWDER, FOR SUSPENSION
Route Of Administration
ORAL
Atc Code
J01CR02
Atc Item Name
amoxicillin and beta-lactamase inhibitor
Pharma Manufacturer Name
MEDOCHEMIE SINGAPORE PTE. LTD.
Active Ingredients
AMOXYCILLIN TRIHYDRATE EQV AMOXYCILLIN
125 mg/5 ml
CLAVULANATE POTASSIUM EQV CLAVULANIC ACID
31.25 mg/5 ml
AMOXYCILLIN TRIHYDRATE EQV AMOXYCILLIN
125 MG/5 ML
CLAVULANATE POTASSIUM EQV CLAVULANIC ACID
31.25 MG/5 ML
Approved
Quick Info
Agency
HSA
Country
🇸🇬
Approval Date
Jan 20, 1999
Approval ID
0224932aeecc5dd1
Type
Therapeutic
Back to HSA Approvals
